

Review

Neuronal Regulation of eIF2 α Function in Health and Neurological DisordersStephanie L. Moon,¹ Nahum Sonenberg,² and Roy Parker^{1,3,*}

A key site of translation control is the phosphorylation of the eukaryotic translation initiation factor 2 α (eIF2 α), which reduces the rate of GDP to GTP exchange by eIF2B, leading to altered translation. The extent of eIF2 α phosphorylation within neurons can alter synaptic plasticity. Phosphorylation of eIF2 α is triggered by four stress-responsive kinases, and as such eIF2 α is often phosphorylated during neurological perturbations or disease. Moreover, in some cases decreasing eIF2 α phosphorylation mitigates neurodegeneration, suggesting that this could be a therapeutic target. Mutations in the γ subunit of eIF2, the guanine exchange factor eIF2B, an eIF2 α phosphatase, or in two eIF2 α kinases can cause disease in humans, demonstrating the importance of proper regulation of eIF2 α phosphorylation for health.

EIF2 α Is a Major Nexus of Translation Regulation in Neurological Health and Disease

The regulation of translation is an important aspect of the control of eukaryotic gene expression, and most commonly occurs during the initiation phase of translation. Initiation of translation is a multistep process wherein the mRNA–protein complex (mRNP) recruits a multifactor complex (MFC) containing the initiation factors eIF1, eIF3, and eIF5, as well as the eIF2 complex bound to GTP and the initiator tRNA, facilitating delivery of the ternary complex to the 40S ribosomal subunit [1] (Figure 1). The MFC is most commonly recruited to the mRNA by the eIF4F complex which recognizes and binds to the 5' cap structure and positions the MFC to scan from the 5' end to the AUG initiation codon. Once the AUG is recognized, hydrolysis of GTP by eIF2 commits the 40S ribosome to translation initiation and leads to the recruitment of the 60S subunit and entry into the elongation phase of translation initiation. After release of eIF2–GDP from the ribosome, GDP is exchanged for GTP by the guanine nucleotide exchange factor (GEF) eIF2B, preparing the eIF2 complex for another round of initiation.

The exchange of GDP for GTP on the heterotrimeric eIF2 complex by the eIF2B complex has emerged as a major node of translation control (Figure 2). In humans, four distinct kinases can be activated by various intracellular cues to phosphorylate the eIF2 α subunit of the eIF2 complex on serine 51 (in humans) [2,3]. Generally, PERK (protein kinase R-like endoplasmic reticulum kinase) phosphorylates eIF2 α in response to unfolded proteins in the endoplasmic reticulum (ER) as part of the **unfolded protein response** (UPR) (see Glossary), while the eIF2 α kinases protein kinase R (PKR), heme-regulated inhibitor (HRI), and general control nonrepressible 2 (GCN2) respond to double-stranded (ds)RNA, oxidative stress, and nutrient deprivation and UV, respectively. However, activation of these kinases is not always restricted to specific stimuli. For example, in addition to UV and nutrient deprivation stress, the UPR can activate GCN2 [4]. The diversity of inputs that trigger eIF2 α kinase activation in general and in neurons has not been fully elaborated.

Highlights

Phosphorylation of eIF2 α is a key regulatory target for translation control that is important in regulating translation during normal and stress conditions.

Emerging data highlight that eIF2 α phosphorylation is crucial in neuronal function and impacts synaptic plasticity as well as being inappropriately increased in numerous neurodegenerative diseases.

Mutations in components of the eIF2 α phosphorylation circuit give rise to human diseases, often including neurological and/or neurodegenerative pathologies.

In model systems of neurological disease with perturbed eIF2 α function, therapeutic restoration of proper eIF2 α control can decrease the severity of disease via targeting of eIF2 α kinases or phosphatases, or by mitigating phospho-eIF2 α activity.

The regulation of eIF2 α phosphorylation is a promising therapeutic target for the treatment of neurological diseases.


¹Department of Chemistry and Biochemistry, University of Colorado, Boulder, CO 80303, USA

²Department of Biochemistry and Goodman Cancer Research Centre, McGill University, Montreal, QC H3A 1A3, Canada

³Howard Hughes Medical Institute, University of Colorado, Boulder, CO 80303, USA


*Correspondence: Roy.Parker@colorado.edu (R. Parker).





Trends in Molecular Medicine

Figure 1. The Translation Initiation Pathway in Eukaryotes Comprises Several Key Steps. First, the eukaryotic initiation factor (eIF) 2B complex reloads the eIF2 complex with GTP to enable ternary complex formation. Next, the 43S preinitiation complex assembles and recruits mRNA to be translated. Scanning commences to then enable start codon recognition, and translation initiates upon formation of the 80S complex.



Trends in Molecular Medicine

Figure 2. The Eukaryotic Initiation Factor (eIF) 2 Complex Is a Crucial Regulatory Nexus for Translation Initiation. The α subunit of the eIF2 complex is phosphorylated (P) by any of four kinases [protein kinase R-like endoplasmic reticulum kinase (PERK), general control nonderepressible 2 (GCN2), heme-regulated inhibitor (HRI) and protein kinase R (PKR)] in response to stress, and is dephosphorylated by stress-induced (GADD34, growth arrest and DNA damage inducible protein 34) or constitutively expressed (CREP, constitutive revertor of eIF2 α phosphorylation) phosphatases. Phospho-eIF2 α inhibits the eIF2B complex, reducing guanine exchange factor activity and limiting translation initiation.

Glossary

Amyloid β ($A\beta$) aggregates:

formed upon cleavage of the amyloid precursor protein, amyloid β peptides are highly prone to aggregation. Extracellular $A\beta$ aggregates are implicated in Alzheimer's disease pathogenesis.

Integrated stress response (ISR):

a conserved response to extrinsic and intrinsic cellular stresses that causes global suppression of translational initiation through reversible phosphorylation of eIF2 α and selective expression of stress-induced genes at the levels of transcription and translation.

MEHMO syndrome: a rare syndrome defined by mental retardation, epileptic seizures, hypogonadism, microcephaly, and obesity caused by mutations in the *EIF2S3* gene, which encodes the gamma subunit of the eIF2 complex.

RAN (Repeat-associated non-AUG) translation: translation of repeat expansion-containing RNAs in multiple open reading frames through non-canonical (non-AUG) translation initiation, leading to generation of mono-, di-, tetra-, and penta-peptides.

Repeat expansion diseases: a class of neurological disorders including Huntington disease, myotonic dystrophy, and fragile X

Phosphorylation of eIF2 α increases its affinity for the GEF eIF2B, and thereby limits the exchange of GDP for GTP [5]. Of note, under conditions of increased tRNA and eIF2- $\gamma\beta$ levels, the α subunit of the eIF2 heterotrimer is unnecessary for ternary complex formation and translation in yeast [6]. Phosphorylation of eIF2 α reduces the concentration of eIF2-GTP complexes, and thereby decreases bulk translation. However, mRNAs that contain upstream open reading frames (uORFs) can actually exhibit increased translation from the major ORF because the kinetics of eIF2-GTP and eIF3 reassociation with scanning ribosomes are slow



Unstressed: abundant ternary complex**Stressed: limited ternary complex**

Figure 3. Translation Initiation of Mammalian Activating Transcription Factor 4 (ATF4) mRNA Harboring Inhibitory Upstream Open Reading Frames (uORFs) Is Enhanced During Stress when the Ternary Complex Is Limited. Adapted, with permission, from [22].

enough to bypass the upstream inhibitory uORFs [7] (Figure 3). Similarly, mRNAs that utilize non-canonical translation initiation mechanisms such as internal ribosome entry sites (IRESs) can show increased translation with eIF2 α phosphorylation [8,9]. Further, different stresses can cause similar and distinct changes in the functional transcriptome (corresponding to the activation of specific eIF2 α kinases), as has been shown in studies in mouse liver cells [10,11], likely as a result of either eIF2 α -independent stress-activated gene regulation mechanisms or cell type-specific differences in the relative abundances of each kinase. Thus, eIF2 α phosphorylation is important in the downregulation of bulk translation under a wide variety of conditions, but is equally (or even more) important in allowing the enhanced translation of specific mRNAs.

The phosphorylation of eIF2 α in response to a wide variety of stresses is a key part of the overall response to stress, which is referred to as the **integrated stress response (ISR)** [2,12]. The ISR involves initial activation of an eIF2 α kinase (e.g., PERK), leading to eIF2 α phosphorylation, and a decrease in bulk translation activity with enhanced translation of some specific mRNAs. The enhanced translation of specific mRNAs, such as those encoding transcription factors ATF4 and CHOP, leads to transcriptional induction of downstream genes which modulate the recovery from stress, or, if the stress is too extreme, can trigger apoptosis (reviewed in [13]).

Evidence now shows that the control of eIF2 α phosphorylation plays important roles in neurons, both in regulating synaptic plasticity and in response to neurodegenerative diseases. This regulation is complex because all four eIF2 α kinases are expressed in the brain, although HRI expression is very low (reviewed in [14]). Of note, differential abundances of each kinase in

mental retardation syndrome caused by repeat expansion mutations that lead to pathogenic loss or gain of function.

Tau oligomers: the neuronal microtubule-associated protein tau can aggregate and form intracellular tau oligomers and neurofibrillary tangles, histological hallmarks implicated in the pathogenesis of numerous tauopathies including Alzheimer's disease and frontotemporal dementia.

Unfolded protein response (UPR): a coordinated cellular response to endoplasmic reticulum (ER) stress that activates ATF6 (activating transcription factor 6), PERK (protein kinase R-like endoplasmic reticulum kinase), and IRE1 (inositol-requiring enzyme 1) to reprogram transcriptional and post-transcriptional gene regulation, ultimately to reduce cellular protein production and enhance protein folding capacity in the ER.

Vanishing White Matter Disease (VWMD): a rare fatal leukodystrophy caused by mutations in genes encoding any subunit of the EIF2B complex. Episodic, progressive deterioration of the white matter can occur following trauma or illness.

Wolcott-Rallison syndrome: a rare syndrome due to mutations in PERK (protein kinase R-like endoplasmic reticulum kinase) that causes microcephaly, intellectual disability, developmental delays, non-autoimmune diabetes, liver and renal dysfunction, and rarely neurodegeneration in childhood.

different brain regions could confer specific functional outcomes upon stress in disease contexts. Moreover, mutations that alter this regulatory circuit can have dramatic deleterious consequences that cause disease. We review below the contributions of eIF2 α phosphorylation to neuronal health in both normal and disease contexts.

eIF2 α Phosphorylation Modulates Synaptic Plasticity

Numerous observations provide genetic data that eIF2 α phosphorylation affects synaptic plasticity (reviewed in depth in [14,15]). For example, mice heterozygous for the S51A mutation, which prevents eIF2 α phosphorylation by changing the phosphorylation site, have enhanced long-term potentiation (LTP) and memory (LTM) [16]. Similarly, an increase in PKR activity in hippocampal neurons impaired long-lasting (L)-LTP and LTM in mice [17], while hippocampal infusion of sal003, a small compound that inhibits dephosphorylation of phospho (p)-eIF2 α , limited L-LTP and LTM [16]. Moreover, consistent with PKR activity limiting memory formation, inhibition or depletion of PKR enhances learning and memory in mice [18].

The role of eIF2 α phosphorylation in memory formation is complex, and alterations in eIF2 α phosphorylation can have different effects depending on the experimental context. For example, mice lacking the GCN2 kinase show a lower threshold for L-LTP with weak training regimens, but are deficient at memory consolidation with stronger training paradigms [19]. The dual effects of alterations in eIF2 α phosphorylation on learning and memory highlights that this is a crucial regulatory site and needs to be able to be modulated in multiple ways for the appropriate outcome.

The mechanism by which eIF2 α phosphorylation affects L-LTP and LTM is likely to involve altering the translation of specific neuronal mRNAs that contain uORFs, and therefore will have enhanced translation when eIF2 α is phosphorylated. For example, the activating transcription factor 4 (ATF4) mRNA has two uORFs, and the ATF4 mRNA shows increased translation at the second downstream uORF when eIF2 α is phosphorylated [20–22] (Figure 3). *ATF4* encodes a transcription factor that can induce downstream genes, and also binds to and inhibits CREB, a key transcriptional factor for activating mRNAs required for synaptic plasticity [23]. Consistent with ATF4 being an important target in this control circuit, eIF2 α phosphorylation generally correlates with increased ATF4 expression and impaired L-LTP and LTM, leading to defects in memory and learning [17,19,24]. Correspondingly, inhibition of eIF2 α dephosphorylation with Sal003 in hippocampal slices from *ATF4*^{−/−} mice had no effect on L-LTP (e.g., [16]). Thus, regulation of ATF4 translation by eIF2 α phosphorylation is likely to play an important role in the modulation of L-LTP and LTM.

Notably, recent work demonstrated that translation initiation on the second ATF4 uORF is blocked under normal conditions by m⁶A methylation because depletion of the demethylase ALKBH5 (alkB homolog 5, RNA demethylase) suppressed ATF4 production, while depletion of the methyltransferase METTL3 (methyltransferase-like 3) caused increased *ATF4* induction during amino acid deprivation stress [25]. This implies that ATF4 regulation and, as such, the effects of eIF2 phosphorylation on synaptic plasticity, may be affected by m⁶A modification of mRNAs.

One anticipates that altered translation of multiple other neuronal mRNAs in response to eIF2 α phosphorylation will also affect synaptic modulation. Several other neuronal mRNAs have uORFs similar to ATF4, and those mRNAs will likely have increased translation rates upon eIF2 α phosphorylation ([15] for review). For example, *GADD34* mRNA has two uORFs and its translation during eIF2 α phosphorylation would initiate a negative feedback loop leading to

dephosphorylation of eIF2 α [26,27]. Similarly, the mRNA for protein kinase M(ζ), which is required for memory formation, has seven uORFs and has been proposed to exhibit decreased translation when PERK is activated [28]. Therefore, the post-transcriptional regulation of mRNAs at the level of translation is one mechanism by which neuronal cell function is modulated.

Pharmacological Modulation of eIF2 α Phosphorylation


The effect of eIF2 α phosphorylation on neuronal function identifies this circuit as a potential target for pharmacological intervention. Three classes of drugs have been identified that affect various aspects of this control process (Figure 4). Several inhibitors of the eIF2 kinases have been identified (reviewed in [29]). For example, the PERK inhibitor I, GSK2606414 [30], has been used in many experiments to manipulate eIF2 α phosphorylation in animals [31,32]. Similarly, various PKR inhibitors have also been used in neuronal contexts (e.g., [33,34]). Screens have been performed to identify inhibitors of HRI and GCN2 (reviewed in [29]), and the GCN2 compounds appear to be effective in tissue culture models [35]. In addition, compounds that inhibit GADD34/PP1c or CREP/PP1c phosphatase action on eIF2 have been identified. For example, the Sal003 compound, which is an analog of salubrinal, is a cell-permeable compound that inhibits PP1c-mediated dephosphorylation of eIF2 α [36]. Finally, a novel compound, ISRIB, has been identified that suppresses the negative effects of eIF2 phosphorylation [37]. While these compounds are useful research tools, the continued identification and refinement of these and other pharmacological tools to manipulate eIF2 α phosphorylation in neurons will be an important area for future drug discovery. Special emphasis should be placed on evaluating the degree to which the ISR is perturbed by therapeutic modulation because complete and/or chronic inhibition or activation of components of the ISR could itself promote disease.

eIF2 α Phosphorylation Occurs in Many Brain Perturbations and Degenerative Diseases

A striking observation is that eIF2 α phosphorylation, and/or activation of aspects of the ISR, occur in a wide variety of brain perturbations and neurological diseases. For example, eIF2 α phosphorylation, stress-induced gene expression, and/or activated eIF2 α kinases are seen in patient tissues and models of traumatic brain injury [37–39], Alzheimer's disease [40–42], amyotrophic lateral sclerosis [31,43], **repeat expansion diseases** [44–48], Parkinson's disease [49], and a wide variety of leukodystrophies (reviewed in [50,51]; including Charcot–Marie–Tooth disease [52] and Pelizaeus–Merzbacher disease [53,54]). Thus, activation of the ISR and phosphorylation of eIF2 α is a common factor in many neurodegenerative diseases.

Different mechanisms contribute to activating kinases of eIF2 α in these disease conditions (Table 1). For example, in several hypomyelination diseases, point mutations affecting the folding of very highly expressed proteins that traverse through the ER lead to the accumulation of unfolded proteins in the ER and trigger an unfolded protein response and PERK activation [52–56]. Similarly, **amyloid β (A β) aggregates** and **tau oligomers** in Alzheimer's disease models can trigger the UPR through their association with the ER to activate PERK, GCN2, or PKR [28,57–60], and prion-like TDP-43 aggregates can also induce eIF2 α phosphorylation [31,46]. Therefore, the aberrant accumulation of misfolded or aggregation-prone proteins can contribute to ISR activation in many neurological disorders.

Neuroinflammation, which is widely observed in many neurodegenerative disorders, is also thought to contribute to activation of the ISR and, conversely, can also result from chronic ISR activation (reviewed in [61]) because cytokines and NF- κ B are upregulated during the ISR



Trends in Molecular Medicine

Figure 4. Small-Molecule Modulators of Phospho (p)-Eukaryotic Initiation Factor (eIF) 2 α Activity. These include Inhibitors of the eIF2 α kinases PERK (protein kinase R-like endoplasmic reticulum kinase) [30,130], HRI (heme-regulated inhibitor) [131–133], GCN2 (general control nonderepressible 2) [35], PKR (protein kinase R) [134], p-eIF2 α phosphatase GADD34 (growth arrest and DNA damage-inducible protein 34) [36,135], and an inhibitor of p-eIF2 α activity that increases eIF2B function [37].

[3,62,63]. In models of Alzheimer's disease, the proinflammatory cytokine TNF- α is required for activation of PKR and subsequent phosphorylation of eIF2 α triggered by A β oligomers [41]. Similarly, demyelinating lesions in patients and murine models of multiple sclerosis exhibit elevated markers of ER stress [64–66], and interferon (IFN)- γ causes ER stress in oligodendrocytes [67–69]. This may occur via rapid upregulation of protein biosynthesis that burdens

Table 1. Chronic Activation of Stress-Response Pathways Resulting in eIF2 α Phosphorylation Is a Common Occurrence in Neurological Disease^a

Disease	Potential stressor	Stress-activated kinase	Refs
Prion diseases (e.g., infectious prion disease, Creutzfeldt–Jakob disease)	RNA–protein aggregates, protein aggregates	PKR	[76–80]
Repeat-expansion diseases (e.g., amyotrophic lateral sclerosis/ frontotemporal dementia, Huntington's disease)	Protein aggregates, RNA–protein aggregates, peptides from RAN translation, dsRNA-like structures	PERK, PKR	[31,46,48,74,75]
Alzheimer's disease (familial or associated with Down's syndrome)	A β protein aggregates, tau oligomers, TNF- α	PKR, PERK, GCN2	[28,41,57–60]
Multiple sclerosis and inflammatory leukodystrophy models	IFN- γ -mediated translation induction?	PERK, PKR	[67–73]
Heritable hypomyelination disorders (e.g., Charcot–Marie–Tooth disease, Pelizaeus–Merzbacher disease)	Misfolded, highly abundant oligodendrocyte/Schwann cell proteins retained in the ER	PERK	[51,53–56,82]
Parkinson's disease, Lewy body dementia	Defective mitochondria, protein aggregates	PERK	[49,94,136]

^aAbbreviations: PKR, protein kinase R; PERK, protein kinase R-like ER kinase; GCN2, general control nonderepressible 2; TNF- α , tumor necrosis factor α .

the ER [70] because treatment with IFN- γ substantially alters the functional transcriptome [71]. It has also been suggested that IFN- γ mRNA can activate PKR, thereby causing phosphorylation of eIF2 α and suppressing its own expression [72,73]. Neuroinflammation may be a key factor in contributing to hyperactivation of the ISR in neurodevelopmental and degenerative disorders.

A third potential mechanism for the activation of eIF2 α kinases is through pathogenic or disease-associated RNAs generated in disease contexts. Brain tissue from patients with Huntington's disease, a repeat-expansion disease caused by trinucleotide repeats in the *HTT* gene, or from mouse models of the disease, have higher levels of activated PKR [48]. Because PKR could be copurified with *HTT* mRNA containing repeats, but not with wild-type *HTT* mRNA from patient-derived brain tissue lysates [48], and mutant *HTT* and other RNAs with pathogenic repeat expansions may form dsRNA-like structures [74,75], it is possible that PKR can bind to repeat expansion-containing RNAs as substrates to activate the ISR.

PKR may also be activated by some RNA–protein complexes. For example, the conversion of cellular prion protein to the pathogenic form is enhanced by RNA [76,77], and prions can form RNA–protein aggregates [78,79] that are capable of activating PKR [80]. Similarly, the presence of large stress granules, which are sizable assemblies of non-translating mRNPs, can cause PKR activation [81]. Therefore, aberrant RNAs and RNP complexes could also contribute to ISR activation through PKR signaling in various neurodegenerative conditions.

Protective Effects of eIF2 α Phosphorylation in Neurological Disease Contexts

Although the phosphorylated form of eIF2 α is observed in a variety of neurological disorders, phosphorylation of eIF2 α could in principle be beneficial to neurons or glial cells. Murine models of hypomyelination and demyelination disorders have lent support to the idea that translational suppression during stress reduces the burden of protein and/or lipid biosynthesis in the ER of

myelin-forming oligodendrocytes, resulting in diminished mRNA translation and alleviating disease. For example, mouse models of Charcot-Marie-Tooth disease that exhibit chronic UPR activation can be partially rescued by the inactivation or depletion of the p-eIF2 α phosphatase GADD34 [55,82,83], which causes an increase in the level of p-eIF2 α and a concomitant reduction in protein biosynthesis. Correspondingly, treatment with salubrinal partially rescues demyelination due to IFN- γ treatment in cultured hippocampal slices [84]. Similarly, activation of an ER stress response in a mouse model of multiple sclerosis before disease onset was protective and limited disease severity [69]. Finally, depletion of the eIF2 α kinase PERK exacerbates IFN- γ -induced oligodendrocyte and myelin loss [67].

Several studies have also demonstrated that p-eIF2 α plays a positive role in the context of other neurological disorders which do not primarily result in dysmyelination. For instance, salubrinal treatment generally protects cells from apoptosis due to chronic ER stress [36], reduces pathogenesis in a model of traumatic brain injury [85], and reduces excitotoxic cell death in a murine model of epilepsy [86]. Therefore, elevation of p-eIF2 α levels appears to be beneficial in particular disease contexts.

Detrimental Effects of eIF2 α Phosphorylation in Neurological Disease Contexts

Because constitutive activation of the ISR can lead to cell death, strong and chronic eIF2 α phosphorylation could contribute to cell death and disease. For example, IFN- γ inhibits remyelination in association with ISR activation in cuprizone-treated and experimental autoimmune encephalitis mouse models [68], and causes apoptosis of oligodendrocytes and hypomyelination in rat oligodendrocytes in culture [67]. In support of this concept, small-molecule inhibitors of the ISR including ISRIB, which increases the activity of eIF2B and reduces the inhibitory effect of p-eIF2 α to block translational suppression in biochemical assays with purified proteins and in a variety of mammalian cell cultures [87,88], confer beneficial effects in many different disease situations. Specifically, ISRIB enhances memory consolidation and learning [37], protects against cognitive impairments due to traumatic brain injury by improving long-term potentiation in the hippocampus [39], and rescues defects in sociability and heightened anxiety in a mouse model of neuropsychiatric disorders including schizophrenia and bipolar disorder [89]. ISRIB also reduces toxicity of amyloid- β in a neuronal cell culture model of Alzheimer's disease [90] and limits neuronal loss and spongiform pathology in a murine model of infectious prion disease [91]. Therefore, directly targeting GEF activity of the eIF2B complex can ameliorate some aspects of neurological disease, although it is formally possible that ISRIB has additional off-target effects that could change the functional transcriptome.

A recently reported chemical screen yielded two small molecules, dibenzoylmethane and trazodone (an antidepressant), that repress the activity of a CHOP reporter in Chinese hamster ovary cells [92] during tunicamycin (ER) stress to levels similar to those observed with ISRIB treatment [93]. It was hypothesized that these drugs may increase ternary complex levels through a mechanism similar to that of ISRIB because global translation activity was increased upon treatment of hippocampal slices from diseased mice (described below) with trazodone or dibenzoylmethane, and levels of p-eIF2 α remain unchanged in the presence of either drug. Importantly, treatment with trazodone or dibenzoylmethane significantly extended lifespan and reduced neuronal loss in a mouse model of infectious prion disease, and partially rescued pathology in a mouse model of frontotemporal dementia [93]. Therefore, increasing translation activity without altering p-eIF2 α levels (perhaps by modulating ternary complex levels) may serve as an important therapeutic option for alleviating neuropathogenesis.

Depletion of eIF2 α kinases can also confer neuroprotective activity in some contexts. Genetic depletion of either PERK or GCN2 enhances spatial memory and rescues LTP defects caused by A β in a murine Alzheimer's disease model [28]. PERK inhibitor I (GSK2606414) reduces neuronal loss in *Drosophila* models of early-onset Parkinson's disease [94], and suppresses TDP-43 toxicity in *Drosophila* and murine neuronal culture models of amyotrophic lateral sclerosis [31]. In addition, the PERK inhibitor I is neuroprotective in a murine model of frontotemporal dementia [95], and prevents clinical disease and neurodegeneration in mice infected with prions [96]. Targeting PKR also improves neurologic outcomes in several disease contexts. The PKR inhibitor C16 prevents neuronal apoptosis induced by excitotoxicity in rats [34], and genetic ablation of PKR inhibits neuroinflammation associated with A β accumulation [97]. Further, neurodegeneration produced by thiamine deficiency can be rescued in mice through treatment with PKR inhibitors [33]. The observation that pharmacological suppression of p-eIF2 α -mediated translational repression is beneficial in many disease contexts therefore indicates that activation of the ISR can contribute to neuropathology.

An additional intriguing pathogenic outcome of eIF2 α phosphorylation is the selective increase in **repeat-associated non-AUG (RAN) translation** [46,47]. **RAN translation** is a non-canonical type of translation that is observed in repeat-expansion diseases including amyotrophic lateral sclerosis, spinocerebellar ataxia type 8, fragile X tremor ataxia syndrome, and Huntington's disease (reviewed in [98,99]). RAN translation occurs on multiple different repeat expansion-containing RNAs in any frame, producing mono-, di-, tetra-, and pentapeptide repeat-expansion proteins [100–103]. These polypeptides accumulate in neurons and other tissues, and can be neurotoxic [99,103]. Because repeat expansions can cause stress-inducing protein and/or RNA aggregates (Table 1), and RAN translation is upregulated when translation is downregulated during stress, targeting the ISR may prove to be doubly important as a therapeutic mechanism for these disorders. Indeed, treatment of cell cultures with ISRIB reduced RAN translation during stress [46], while treatment with Sal003, an analog of salubrinal that inhibits GADD34 and increases p-eIF2 α levels, causes increased RAN translation [47]. Therefore, modulation of the ISR generally serves as a key pharmaceutical approach in many neurodegenerative and neurodevelopmental diseases.

In sum, these observations support the idea that there is an optimal range of translation activity that needs to be maintained in stressed or unstressed conditions for proper control of the ISR and optimal cell health/viability. For instance, in myelination disorders it is thought that the stage of oligodendrocyte maturation (which dictates the level of protein and lipid production in these cells) and the degree of ER stress caused by IFN- γ play a role in determining whether an ISR is beneficial or detrimental in the context of hypomyelination disorders [67–70]. However, the beneficial effects of reducing eIF2 α phosphorylation in multiple contexts indicate that this is an exciting area for the development of new therapeutics.

Mutations in Components of the eIF2 α GDP–GTP Cycle Cause Human Diseases

Consistent with proper regulation of eIF2 α phosphorylation being important for health, mutations in several components of this circuit give rise to human diseases (Table 2). For example, over 120 different recessive mutations in any of the five subunits of the GEF eIF2B give rise to **vanishing white matter disease** (VWMD) [104,105]. VWMD is one of the most common forms of childhood leukodystrophy, although symptoms can manifest at any age. Patients with VWMD often exhibit developmental delays, spasticity, and ataxia, with progressive white matter loss and ovarian dysgenesis. The severity of VWMD is inversely correlated with age of symptom onset, and progressive white matter loss is often observed following physiological stresses

Table 2. Several Neurological and Neurodevelopmental Disorders Are Caused by Mutations in Key Regulators of the Integrated Stress Response^a

Syndrome/neurological disease	Heritability	Zygosity	Affected gene	Mutations	Refs
Global developmental delay, microcephaly, intellectual disability, hypomyelination	Autosomal recessive	Homozygous	<i>PPP1R15B</i> (also known as <i>CREP</i>)	R658C	[127,128]
MEHMO syndrome: severe X-linked intellectual disability with hypomyelination, spasticity, and epilepsy	X-linked recessive	Hemizygous	<i>EIF2S3</i> (also known as <i>EIF2G</i>)	I222T, I259M, S108R, V151L, I465SfsTer4	[115–117,136]
Vanishing white matter disease: encephalopathy, hypomyelination, spasticity, ataxia, seizures, progressive white matter loss (especially after trauma or illness) at any age	Autosomal recessive	Homozygous or compound heterozygous	<i>EIF2B1</i> , <i>EIF2B2</i> , <i>EIF2B3</i> , <i>EIF2B4</i> , <i>EIF2B5</i>	<i>EIF2B5</i> R113H (most common) > 120 identified (see [105])	[104–106,137–139]
Wolcott–Rallison syndrome: microcephaly, developmental delay, intellectual disability, neurodegeneration in childhood	Autosomal recessive	Homozygous or compound heterozygous	<i>EIF2AK3</i> (also known as <i>PERK</i>)	R587Q, E331X, R902X, IVS14 + 1G-A, K345fsTer1, Q523fsTer4	[122,124,140–142]

^aAbbreviations: PPP1R15B, protein phosphatase 1 regulatory subunit 15B; EIF2S2, eukaryotic initiation factor 2 subunit 3; MEHMO, mental retardation, epileptic seizures, hypogonadism, microcephaly, obesity; EIF2B, eukaryotic initiation factor 2B; EIF2AK3, eukaryotic translation initiation factor 2 α kinase 3.

including physical trauma, fear, and illness [105,106]. Disease-causing mutations can affect the abundance, guanine exchange activity, and/or assembly of the eIF2B complex, any of which theoretically could reduce cellular translation activity by reducing the pool of eIF2–GTP that is available for ternary complex formation [105,107–109]. However, biochemical analyses have revealed no single mechanistic explanation for all cases of VWMD [105,110]. Instead, it is likely that a spectrum of outcomes occurs depending on the mutated subunit and the degree to which the eIF2B complex is compromised.

Because eIF2B is a key regulatory node in the ISR, and is also responsible for the regeneration of the GTP–eIF2 complex to enable translation initiation, mutations that cause VWMD are likely to interfere with ISR resolution and/or normal translation activity in the cell. The ISR can be activated in cells of the brain upon trauma [38,111] and in neuroinflammatory contexts [67–69], and progressive episodes of white matter loss following these insults are noted in patients with VWMD. This observation supports the idea that perturbed ISR induction or resolution could result from disease-causing mutations in *EIF2B* genes. Consistent with eIF2B mutations affecting the ISR, VWMD patient cells typically have normal levels of translation in the absence of stress, but at least in some contexts hyper-repress translation during stress, fail to fully induce the GADD34 protein, and therefore are defective in stress recovery [112]. The VWMD phenotype is likely to also be affected by alterations in the proteome of eIF2B mutant cells, as well as by defects in inducing key molecules that promote remyelination following injury [113–115].

In a disease related to VWMD, mutations in the gene encoding the third subunit of the eIF2 complex (*EIF2G/EIF2S3*), cause a severe X-linked intellectual disability called **MEHMO** (mental retardation, epileptic seizures, hypogonadism and hypogonitalism, microcephaly, and obesity) syndrome [116–118]. **MEHMO syndrome** is characterized by severe intellectual disability,

cognitive and motor delays, microcephaly, hypomyelination, obesity, and hypogenitalism, and many patients also suffer from non-autoimmune diabetes mellitus and epilepsy [118]. As in VWMD, a spectrum of phenotypes are caused by different *EIF2S3* mutations in MEHMO syndrome. Notably, illness-aggravated pathologies associated with MEHMO syndrome have been reported, as seen in many VWMD cases [118]. Specific mutations in *EIF2S3* dramatically reduce cell growth/viability, the fidelity of translation initiation (as measured using reporters that assess AUG start site selection versus UUG start-site selection), and cause increased stress-induced gene expression in yeast models, whereas other mutations do not [116,118]. Analysis of a single-patient fibroblast sample from a patient with MEHMO syndrome revealed elevated CHOP expression at the protein and mRNA levels, indicating that some mutations in *EIF2S3* may reduce eIF2 activity and cause a chronic stress state [118]. Because some disease-causing mutations in *EIF2S3* perturb the interaction of eIF2 γ with eIF2B β , it is possible that constitutively reduced translation activity contributes to a chronic stress response in patient cells. Further studies should be undertaken to determine how the full range of *EIF2S3* mutations that cause MEHMO syndrome affect the ISR, and assess drugs targeting the ISR as therapeutic intervention strategies.

Mutations in eIF2 α Kinases Lead to Human Diseases

Mutations in two of the eIF2 α kinases also give rise to specific human pathologies that are not restricted to the nervous system. Recessive mutations in *GCN2* lead to familial pulmonary capillary hemangiomatosis [119], or in other patients to a related pulmonary veno-occlusive disease (PVOD) [120,121]. Although these are not neuronal dysfunctions, one anticipates that these patients may have altered neuronal properties given the changes in *GCN2* function. Similarly, mutations in *PERK* lead to **Wolcott-Rallison syndrome**, a rare autosomal recessive form of diabetes [122,123]. Wolcott-Rallison syndrome patients often display some intellectual deficiencies, illustrating the role of *PERK* in proper neuronal development and function [123,124]. A rare allele of *PERK* (*EIF2AK3*) has also been identified that increases the risk of the tauopathy progressive supranuclear palsy (PSP), although how this specific alteration of *PERK* leads to PSP is unclear [125]. A patient with Wolcott-Rallison syndrome who had neurodegeneration (neurofibrillary tangles reminiscent of tauopathies, FUS-positivity in neurons as observed in frontotemporal dementia, activation of astrocytes and Bergmann glial cells, and elevated microglia) in childhood was homozygous for a premature stop codon mutation in *PERK* that could encode an inactive truncated form of *PERK* [124]. The observation that loss of these eIF2 α kinases leads to genetic disease again illustrates the importance of proper eIF2 control for health and function.

Mutations in Phosphatases Targeting eIF2 α

A final set of disease mutations affecting the phosphorylation of eIF2 α are recessive mutations in the phosphatase gene *PPP1R15B*, also known as CReP (constitutive revertor of eIF2 α phosphorylation). Like the stress-induced GADD34 protein, CReP is a regulatory subunit of PP1C that functions to dephosphorylate eIF2 when phosphorylated at Ser51. However, CReP is constitutively expressed [126]. These patients develop a multisystem syndrome with diabetes, microcephaly, intellectual disability, hypomyelination, and short stature [127,128], in line with the observation that *Ppp1r15b* deficiency severely impairs the development and growth of mice [129]. Importantly, disease-causing mutations reduce the phosphatase activity of CReP *in vitro* in rat insulin-secreting pancreatic β cell lines [127], and patient-derived cell lines show increased levels of p-eIF2 α [128]. Expression of disease-causing CReP mutants promoted apoptosis in rat primary and insulinoma pancreatic β cell lines [127], and this could contribute to diabetes observed in this syndrome, potentially resulting from chronic and prolonged eIF2 α phosphorylation. Therefore, defects in the regulators of the ISR can also contribute to human neurodevelopmental disease.

Box 1. Clinician's Corner

The control of translation and its regulation in response to stress is a crucial aspect of neuronal function. A key node in translational control is eIF2 α phosphorylation, which downregulates bulk translation and allows selective translation of key mRNAs.

Phosphorylation of eIF2 α is crucial in neuronal function and impacts synaptic plasticity as well as being inappropriately increased in numerous neurodegenerative diseases.

Mutations in several proteins involved in controlling the eIF2 α phosphorylation circuit give rise to human diseases including neurological pathologies.

Compounds targeting the eIF2 α kinases or phosphatases, or abrogating the effect of eIF2 α phosphorylation, are in development. In model systems of neurological disease with perturbed eIF2 α function, therapeutic restoration of proper eIF2 α control can decrease the severity of disease.

In the future, pharmacological manipulation of the control and extent of eIF2 α phosphorylation may be a possible therapy for the treatment of some neurological diseases.

Outstanding Questions

What are the differences in individual cell types that lead to unique responses to perturbation of eIF2 α phosphorylation? The eIF2 α kinases and phosphatases are widely expressed, but perturbation of the pathway often leads to defects in specific cell types for an unknown reason.

What additional regulatory circuits impinge upon components of eIF2 α regulation, and how might they be manipulated for therapeutic benefit? The functional levels of the eIF2B complex affect the response to eIF2 α phosphorylation, but how eIF2B is functionally controlled has not been fully elucidated.

Can effective therapies be developed that use small molecules to restore proper regulation of eIF2 α phosphorylation in disease settings? This is a challenge because eIF2 α phosphorylation is crucial for normal neuronal function, and a balance will be needed between preventing aberrant control through this regulatory site and maintaining its normal functions.

Concluding Remarks and Future Perspectives

Key questions remain in the field of eIF2 α -dependent stress-responsive translation regulation and neuronal disorders (see Outstanding Questions). First, how different cell types and tissue contexts affect the sensitivity to acute and chronic stressors that activate eIF2 α phosphorylation and the ISR, and the diversity in stress-induced gene expression, remain to be fully explored. Such an analysis could yield insight into why defects in the ISR seem to consistently cause neuronal (and often pancreatic) defects. Much research has revealed the main players in the ISR, including the eIF2 α kinases and phosphatases, and has illuminated many of the stress-induced genes that are expressed following eIF2 α phosphorylation. However, whether stress-induced genes are primarily regulated transcriptionally or post-transcriptionally during and after the ISR, and how cell type and disease context alters the identity of these genes, remains to be characterized. Third, future work should focus on the interplay between stress-induced RNA-protein granules and translation regulation during the ISR. Such research could shed light on the mechanisms by which repeat-expansion disorders and TDP-43 (another prion-like RNA-binding protein) mutations confer pathogenesis. Finally, exciting developments have resulted in the elucidation of several compounds (e.g., ISRIB, salubrinol, and PERK inhibitors) that allow us to chemically modulate essential components of the ISR. The utility of these compounds in alleviating a wide variety of neurodevelopmental and neurodegenerative diseases is only now beginning to be appreciated (Box 1). As future research identifies different disease contexts for which these compounds may be effective, tests these compounds in cell culture and animal models, and determines mechanisms for cell- and/or tissue-specific delivery of these compounds, much will be learned about the potential for therapeutic modulation of the ISR in many disease contexts.

Acknowledgments

We thank Anne Webb for assistance with the figures. This work was supported by an award from the Howard Hughes Medical Institute (to R.P.), a Foundation grant from the Canadian Institutes of Health Research (to N.S.), and an Anna and John J. Sie Foundation postdoctoral fellowship (to S.L.M).

References

1. Sonenberg, N. and Hinnebusch, A.G. (2009) Regulation of translation initiation in eukaryotes: mechanisms and biological targets. *Cell* 136, 731–745
2. Pakos-Zebrucka, K. et al. (2016) The integrated stress response. *EMBO Rep.* 17, 1374–1395
3. Wek, R.C. et al. (2006) Coping with stress: eIF2 kinases and translational control. *Biochem. Soc. Trans.* 34, 7–11
4. Hamanaka, R.B. et al. (2005) PERK and GCN2 contribute to eIF2 α phosphorylation and cell cycle arrest after activation of the unfolded protein response pathway. *Mol. Biol. Cell* 16, 5493–5501

5. Pavitt, G.D. *et al.* (1998) eIF2 independently binds two distinct eIF2B subcomplexes that catalyze and regulate guanine-nucleotide exchange. *Genes Dev.* 12, 514–526
6. Erickson, F.L. *et al.* (2001) Minimum requirements for the function of eukaryotic translation initiation factor 2. *Genetics* 158, 123–132
7. Hinnebusch, A.G. *et al.* (2016) Translational control by 5'-untranslated regions of eukaryotic mRNAs. *Science* 352, 1413–1416
8. Komar, A.A. and Hatzoglou, M. (2011) Cellular IRES-mediated translation: the war of ITAFs in pathophysiological states. *Cell Cycle* 10, 229–240
9. Thompson, S.R. (2012) Tricks an IRES uses to enslave ribosomes. *Trends Microbiol.* 20, 558–566
10. Dang Do, A.N. *et al.* (2009) eIF2 α kinases GCN2 and PERK modulate transcription and translation of distinct sets of mRNAs in mouse liver. *Physiol. Genom.* 38, 328–341
11. Donnelly, N. *et al.* (2013) The eIF2 α kinases: their structures and functions. *Cell. Mol. Life Sci.* 70, 3493–3511
12. Ron, D. and Walter, P. (2007) Signal integration in the endoplasmic reticulum unfolded protein response. *Nat. Rev. Mol. Cell Biol.* 8, 519–529
13. Sano, R. and Reed, J.C. (2013) ER stress-induced cell death mechanisms. *Biochim. Biophys. Acta* 1833, 3460–3470
14. Trinh, M.A. and Klann, E. (2013) Translational control by eIF2 α kinases in long-lasting synaptic plasticity and long-term memory. *Neurobiol. Learn. Mem.* 105, 93–99
15. Chesnokova, E. *et al.* (2017) Kinases of eIF2 α switch translation of mRNA subset during neuronal plasticity. *Int. J. Mol. Sci.* 18, E2213
16. Costa-Mattioli, M. *et al.* (2007) eIF2 α phosphorylation bidirectionally regulates the switch from short- to long-term synaptic plasticity and memory. *Cell* 129, 195–206
17. Jiang, Z. *et al.* (2010) eIF2 α phosphorylation-dependent translation in CA1 pyramidal cells impairs hippocampal memory consolidation without affecting general translation. *J. Neurosci.* 30, 2582–2594
18. Zhu, P.J. *et al.* (2011) Suppression of PKR promotes network excitability and enhanced cognition by interferon- γ -mediated disinhibition. *Cell* 147, 1384–1396
19. Costa-Mattioli, M. *et al.* (2005) Translational control of hippocampal synaptic plasticity and memory by the eIF2 α kinase GCN2. *Nature* 436, 1166–1173
20. Harding, H.P. *et al.* (2000) Regulated translation initiation controls stress-induced gene expression in mammalian cells. *Mol. Cell* 6, 1099–1108
21. Lu, P.D. *et al.* (2004) Translation reinitiation at alternative open reading frames regulates gene expression in an integrated stress response. *J. Cell Biol.* 167, 27–33
22. Vattem, K.M. and Wek, R.C. (2004) Reinitiation involving upstream ORFs regulates ATF4 mRNA translation in mammalian cells. *Proc. Natl. Acad. Sci. U. S. A.* 101, 11269–11274
23. Alberini, C.M. (2009) Transcription factors in long-term memory and synaptic plasticity. *Physiol. Rev.* 89, 121–145
24. Trinh, M.A. *et al.* (2012) Brain-specific disruption of the eIF2 α kinase PERK decreases ATF4 expression and impairs behavioral flexibility. *Cell Rep.* 1, 676–688
25. Zhou, J. *et al.* (2018) N6-methyladenosine guides mRNA alternative translation during integrated stress response. *Mol. Cell* 69, 636–647
26. Dalet, A. *et al.* (2017) Protein synthesis inhibition and GADD34 control IFN- β heterogeneous expression in response to dsRNA. *EMBO J.* 36, 761–782
27. Novoa, I. *et al.* (2001) Feedback inhibition of the unfolded protein response by GADD34-mediated dephosphorylation of eIF2 α . *J. Cell Biol.* 153, 1011–1022
28. Ma, T. *et al.* (2013) Suppression of eIF2 α kinases alleviates Alzheimer's disease-related plasticity and memory deficits. *Nat. Neurosci.* 16, 1299–1305
29. Joshi, M. *et al.* (2013) Small molecule modulators of eukaryotic initiation factor 2 α kinases, the key regulators of protein synthesis. *Biochimie* 95, 1980–1990
30. Axten, J.M. *et al.* (2012) Discovery of 7-methyl-5-(1-((3-(trifluoromethyl)phenyl)acetyl)-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo [2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK). *J. Med. Chem.* 55, 7193–7207
31. Kim, H.-J. *et al.* (2014) Therapeutic modulation of eIF2 α phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models. *Nat. Genet.* 46, 152–160
32. Yan, F. *et al.* (2017) Pharmacological inhibition of PERK attenuates early brain injury after subarachnoid hemorrhage in rats through the activation of Akt. *Mol. Neurobiol.* 54, 1808–1817
33. Mouton-Liger, F. *et al.* (2015) PKR downregulation prevents neurodegeneration and β -amyloid production in a thiamine-deficient model. *Cell Death Dis.* 6, e1594
34. Tronel, C. *et al.* (2014) The specific PKR inhibitor C16 prevents apoptosis and IL-1 β production in an acute excitotoxic rat model with a neuroinflammatory component. *Neurochem. Int.* 64, 73–83
35. Robert, F. *et al.* (2009) Blocking UV-induced eIF2 α phosphorylation with small molecule inhibitors of GCN2. *Chem. Biol. Drug Des.* 74, 57–67
36. Boyce, M. *et al.* (2005) A selective inhibitor of eIF2 α dephosphorylation protects cells from ER stress. *Science* 307, 935–939
37. Sidrauski, C. *et al.* (2013) Pharmacological brake-release of mRNA translation enhances cognitive memory. *eLife* 2, e00498
38. Begum, G. *et al.* (2014) Docosahexaenoic acid reduces ER stress and abnormal protein accumulation and improves neuronal function following traumatic brain injury. *J. Neurosci.* 34, 3743–3755
39. Chou, A. *et al.* (2017) Inhibition of the integrated stress response reverses cognitive deficits after traumatic brain injury. *Proc. Natl. Acad. Sci. U. S. A.* 114, E6420–E6426
40. Hoozemans, J.J.M. *et al.* (2009) The unfolded protein response is activated in pretangle neurons in Alzheimer's disease hippocampus. *Am. J. Pathol.* 174, 1241–1251
41. Lourenco, M.V. *et al.* (2013) TNF- α mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer's β -amyloid oligomers in mice and monkeys. *Cell Metab.* 18, 831–843
42. O'Connor, T. *et al.* (2008) Phosphorylation of the translation initiation factor eIF2 α increases BACE1 levels and promotes amyloidogenesis. *Neuron* 60, 988–1009
43. Atkin, J.D. *et al.* (2008) Endoplasmic reticulum stress and induction of the unfolded protein response in human sporadic amyotrophic lateral sclerosis. *Neurobiol. Dis.* 30, 400–407
44. Bando, Y. *et al.* (2005) Double-strand RNA dependent protein kinase (PKR) is involved in the extrastriatal degeneration in Parkinson's disease and Huntington's disease. *Neurochem. Int.* 46, 11–18
45. Carnemolla, A. *et al.* (2009) Rrs1 is involved in endoplasmic reticulum stress response in Huntington disease. *J. Biol. Chem.* 284, 18167–18173
46. Cheng, W. *et al.* (2018) C9orf72 GGGGCC repeat-associated non-AUG translation is upregulated by stress through eIF2 α phosphorylation. *Nat. Commun.* 9, 51
47. Green, K.M. *et al.* (2017) RAN translation at C9orf72-associated repeat expansions is selectively enhanced by the integrated stress response. *Nat. Commun.* 8, 2005
48. Peel, A.L. *et al.* (2001) Double-stranded RNA-dependent protein kinase, PKR, binds preferentially to Huntington's disease (HD) transcripts and is activated in HD tissue. *Hum. Mol. Genet.* 10, 1531–1538
49. Hoozemans, J.J.M. *et al.* (2007) Activation of the unfolded protein response in Parkinson's disease. *Biochem. Biophys. Res. Commun.* 354, 707–711
50. Clayton, B.L.L. and Popko, B. (2016) Endoplasmic reticulum stress and the unfolded protein response in disorders of myelinating glia. *Brain Res.* 1648, 594–602

51. Volpi, V.G. *et al.* (2016) Endoplasmic reticulum protein quality control failure in myelin disorders. *Front. Mol. Neurosci.* 9, 162
52. D'Antonio, M. *et al.* (2009) Myelin under stress. *J. Neurosci. Res.* 87, 3241–3249
53. Roboti, P. *et al.* (2009) Differences in endoplasmic-reticulum quality control determine the cellular response to disease-associated mutants of proteolipid protein. *J. Cell Sci.* 122, 3942–3953
54. Southwood, C.M. *et al.* (2002) The unfolded protein response modulates disease severity in Pelizaeus-Merzbacher disease. *Neuron* 36, 585–596
55. Pennuto, M. *et al.* (2008) Ablation of the UPR-mediator CHOP restores motor function and reduces demyelination in Charcot-Marie-Tooth 1B mice. *Neuron* 57, 393–405
56. Wrabetz, L. *et al.* (2006) Different intracellular pathomechanisms produce diverse myelin protein zero neuropathies in transgenic mice. *J. Neurosci.* 26, 2358–2368
57. Abisambra, J.F. *et al.* (2013) Tau accumulation activates the unfolded protein response by impairing endoplasmic reticulum-associated degradation. *J. Neurosci.* 33, 9498–9507
58. Chang, R.C.C. *et al.* (2002) Phosphorylation of eukaryotic initiation factor-2 α (eIF2 α) is associated with neuronal degeneration in Alzheimer's disease. *Neuroreport* 13, 2429–2432
59. Kondo, T. *et al.* (2013) Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular A β and differential drug responsiveness. *Cell Stem Cell* 12, 487–496
60. Peel, A.L. and Bredesen, D.E. (2003) Activation of the cell stress kinase PKR in Alzheimer's disease and human amyloid precursor protein transgenic mice. *Neurobiol. Dis.* 14, 52–62
61. Sprengle, N.T. *et al.* (2017) Endoplasmic reticulum stress and inflammation in the central nervous system. *Mol. Neurodegener.* 12, 42
62. Deng, J. *et al.* (2004) Translational repression mediates activation of nuclear factor kappa B by phosphorylated translation initiation factor 2. *Mol. Cell Biol.* 24, 10161–10168
63. Shenderov, K. *et al.* (2014) Endoplasmic reticulum stress licenses macrophages to produce mature IL-1 β in response to TLR4 stimulation through a caspase-8- and TRIF-dependent pathway. *J. Immunol.* 192, 2029–2033
64. Cunnea, P. *et al.* (2011) Expression profiles of endoplasmic reticulum stress-related molecules in demyelinating lesions and multiple sclerosis. *Mult. Scler.* 17, 808–818
65. McMahon, J.M. *et al.* (2012) Increased expression of ER stress- and hypoxia-associated molecules in grey matter lesions in multiple sclerosis. *Mult. Scler.* 18, 1437–1447
66. Mhaille, A.N. *et al.* (2008) Increased expression of endoplasmic reticulum stress-related signaling pathway molecules in multiple sclerosis lesions. *J. Neuropathol. Exp. Neurol.* 67, 200–211
67. Lin, W. *et al.* (2005) Endoplasmic reticulum stress modulates the response of myelinating oligodendrocytes to the immune cytokine interferon- γ . *J. Cell Biol.* 169, 603–612
68. Lin, W. *et al.* (2006) Interferon- γ inhibits central nervous system remyelination through a process modulated by endoplasmic reticulum stress. *Brain J. Neurol.* 129, 1306–1318
69. Lin, W. *et al.* (2007) The integrated stress response prevents demyelination by protecting oligodendrocytes against immune-mediated damage. *J. Clin. Invest.* 117, 448–456
70. Lees, J.R. and Cross, A.H. (2007) A little stress is good: IFN- γ , demyelination, and multiple sclerosis. *J. Clin. Invest.* 117, 297–299
71. Su, X. *et al.* (2015) Interferon- γ regulates cellular metabolism and mRNA translation to potentiate macrophage activation. *Nat. Immunol.* 16, 838–849
72. Ben-Asouli, Y. *et al.* (2002) Human interferon- γ mRNA autoregulates its translation through a pseudoknot that activates the interferon-inducible protein kinase PKR. *Cell* 108, 221–232
73. Cohen-Chalamish, S. *et al.* (2009) Dynamic refolding of IFN- γ mRNA enables it to function as PKR activator and translation template. *Nat. Chem. Biol.* 5, 896–903
74. de Mezer, M. *et al.* (2011) Mutant CAG repeats of Huntingtin transcript fold into hairpins, form nuclear foci and are targets for RNA interference. *Nucleic Acids Res.* 39, 3852–3863
75. Sobczak, K. *et al.* (2003) RNA structure of trinucleotide repeats associated with human neurological diseases. *Nucleic Acids Res.* 31, 5469–5482
76. Adler, V. *et al.* (2003) Small, highly structured RNAs participate in the conversion of human recombinant PrP(Sen) to PrP(Res) in vitro. *J. Mol. Biol.* 332, 47–57
77. Deleault, N.R. *et al.* (2003) RNA molecules stimulate prion protein conversion. *Nature* 425, 717–720
78. Gomes, M.P.B. *et al.* (2008) Prion protein complexed to N2a cellular RNAs through its N-terminal domain forms aggregates and is toxic to murine neuroblastoma cells. *J. Biol. Chem.* 283, 19616–19625
79. Kellings, K. *et al.* (1992) Further analysis of nucleic acids in purified scrapie prion preparations by improved return refocusing gel electrophoresis. *J. Gen. Virol.* 73, 1025–1029
80. Goggin, K. *et al.* (2008) Prion protein aggregates are poly(A)⁺ ribonucleoprotein complexes that induce a PKR-mediated deficient cell stress response. *Biochim. Biophys. Acta* 1783, 479–491
81. Reineke, L.C. *et al.* (2012) Large G3BP-induced granules trigger eIF2 α phosphorylation. *Mol. Biol. Cell* 23, 3499–3510
82. D'Antonio, M. *et al.* (2013) Resetting translational homeostasis restores myelination in Charcot-Marie-Tooth disease type 1B mice. *J. Exp. Med.* 210, 821–838
83. Das, I. *et al.* (2015) Preventing proteostasis diseases by selective inhibition of a phosphatase regulatory subunit. *Science* 348, 239–242
84. Lin, W. *et al.* (2008) Enhanced integrated stress response promotes myelinating oligodendrocyte survival in response to interferon- γ . *Am. J. Pathol.* 173, 1508–1517
85. Logsdon, A.F. *et al.* (2014) Altering endoplasmic reticulum stress in a model of blast-induced traumatic brain injury controls cellular fate and ameliorates neuropsychiatric symptoms. *Front. Cell. Neurosci.* 8, 421
86. Sokka, A.-L. *et al.* (2007) Endoplasmic reticulum stress inhibition protects against excitotoxic neuronal injury in the rat brain. *J. Neurosci.* 27, 901–908
87. Sekine, Y. *et al.* (2015) Mutations in a translation initiation factor identify the target of a memory-enhancing compound. *Science* 348, 1027–1030
88. Sidrauski, C. *et al.* (2015) Pharmacological dimerization and activation of the exchange factor eIF2B antagonizes the integrated stress response. *eLife* 4, e07314
89. Kabir, Z.D. *et al.* (2017) Rescue of impaired sociability and anxiety-like behavior in adult Cacna1c-deficient mice by pharmacologically targeting eIF2 α . *Mol. Psychiatry* 22, 1096–1109
90. Hosoi, T. *et al.* (2016) Unique pharmacological property of ISRIB in inhibition of A β -induced neuronal cell death. *J. Pharmacol. Sci.* 131, 292–295
91. Halliday, M. *et al.* (2015) Partial restoration of protein synthesis rates by the small molecule ISRIB prevents neurodegeneration without pancreatic toxicity. *Cell Death Dis.* 6, e1672
92. Harding, H.P. *et al.* (2005) Bioactive small molecules reveal antagonism between the integrated stress response and steroid-regulated gene expression. *Cell Metab.* 2, 361–371
93. Halliday, M. *et al.* (2017) Repurposed drugs targeting eIF2 α -P-mediated translational repression prevent neurodegeneration in mice. *Brain J. Neurol.* 140, 1768–1783
94. Celardo, I. *et al.* (2016) Mitofusin-mediated ER stress triggers neurodegeneration in pink1/parkin models of Parkinson's disease. *Cell Death Dis.* 7, e2271
95. Radford, H. *et al.* (2015) PERK inhibition prevents tau-mediated neurodegeneration in a mouse model of frontotemporal dementia. *Acta Neuropathol.* 130, 633–642
96. Moreno, J.A. *et al.* (2013) Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice. *Sci. Transl. Med.* 5, 206ra138

97. Carret-Rebillat, A.-S. *et al.* (2015) Neuroinflammation and A β accumulation linked to systemic inflammation are decreased by genetic PKR down-regulation. *Sci. Rep.* 5, 8489
98. Cleary, J.D. and Ranum, L.P. (2017) New developments in RAN translation: insights from multiple diseases. *Curr. Opin. Genet. Dev.* 44, 125–134
99. Kapur, M. *et al.* (2017) Regulation of mRNA translation in neurons – a matter of life and death. *Neuron* 96, 616–637
100. Zu, T. *et al.* (2011) Non-ATG-initiated translation directed by microsatellite expansions. *Proc. Natl. Acad. Sci.* 108, 260–265
101. Zu, T. *et al.* (2017) RAN translation regulated by muscleblind proteins in myotonic dystrophy type 2. *Neuron* 95, 1292–1305
102. Ishiguro, T. *et al.* (2017) Regulatory role of RNA chaperone TDP-43 for RNA misfolding and repeat-associated translation in SCA31. *Neuron* 94, 108–124
103. Lee, K.-H. *et al.* (2016) C9orf72 dipeptide repeats impair the assembly, dynamics, and function of membrane-less organelles. *Cell* 167, 774–788
104. Leegwater, P.A. *et al.* (2001) Subunits of the translation initiation factor eIF2B are mutant in leukoencephalopathy with vanishing white matter. *Nat. Genet.* 29, 383–388
105. Pavitt, G.D. and Proud, C.G. (2009) Protein synthesis and its control in neuronal cells with a focus on vanishing white matter disease. *Biochem. Soc. Trans.* 37, 1298–1310
106. Klingelhofer, L. *et al.* (2014) Vanishing white matter disease presenting as opsoclonus myoclonus syndrome in childhood – a case report and review of the literature. *Pediatr. Neurol.* 51, 157–164
107. Fogli, A. *et al.* (2004) Decreased guanine nucleotide exchange factor activity in eIF2B-mutated patients. *Eur. J. Hum. Genet.* 12, 561–566
108. Li, W. *et al.* (2004) Mutations linked to leukoencephalopathy with vanishing white matter impair the function of the eukaryotic initiation factor 2B complex in diverse ways. *Mol. Cell. Biol.* 24, 3295–3306
109. Richardson, J.P. *et al.* (2004) Mutations causing childhood ataxia with central nervous system hypomyelination reduce eukaryotic initiation factor 2B complex formation and activity. *Mol. Cell. Biol.* 24, 2352–2363
110. Liu, R. *et al.* (2011) Severity of vanishing white matter disease does not correlate with deficits in eIF2B activity or the integrity of eIF2B complexes. *Hum. Mutat.* 32, 1036–1045
111. Singleton, R.H. *et al.* (2002) Traumatically induced axotomy adjacent to the soma does not result in acute neuronal death. *J. Neurosci.* 22, 791–802
112. Moon, S.L. and Parker, R. (2018) *EIF2B2* mutations in Vanishing White Matter Disease hyper-suppress translation and delay recovery during the integrated stress response. *RNA* 066563
113. Cabilly, Y. *et al.* (2012) Poor cerebral inflammatory response in eIF2B knock-in mice: implications for the aetiology of vanishing white matter disease. *PLoS One* 7, e46715
114. Gat-Viks, I. *et al.* (2015) Proteomics-level analysis of myelin formation and regeneration in a mouse model for vanishing white matter disease. *J. Neurochem.* 134, 513–526
115. Raini, G. *et al.* (2017) Mutant eIF2B leads to impaired mitochondrial oxidative phosphorylation in vanishing white matter disease. *J. Neurochem.* 141, 694–707
116. Borck, G. *et al.* (2012) eIF2 γ mutation that disrupts eIF2 complex integrity links intellectual disability to impaired translation initiation. *Mol. Cell* 48, 641–646
117. Moortgat, S. *et al.* (2016) Two novel EIF2S3 mutations associated with syndromic intellectual disability with severe microcephaly, growth retardation, and epilepsy. *Am. J. Med. Genet. A* 170, 2927–2933
118. Skopkova, M. *et al.* (2017) EIF2S3 mutations associated with severe X-linked intellectual disability syndrome MEHMO. *Hum. Mutat.* 38, 409–425
119. Best, D.H. *et al.* (2014) EIF2AK4 mutations in pulmonary capillary hemangiomatosis. *Chest* 145, 231–236
120. Eyries, M. *et al.* (2014) EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. *Nat. Genet.* 46, 65–69
121. Langleben, D. (2014) Pulmonary capillary hemangiomatosis: the puzzle takes shape. *Chest* 145, 197–199
122. Delépine, M. *et al.* (2000) EIF2AK3, encoding translation initiation factor 2-alpha kinase 3, is mutated in patients with Wolcott-Rallison syndrome. *Nat. Genet.* 25, 406–409
123. Julier, C. and Nicolino, M. (2010) Wolcott-Rallison syndrome. *Orphanet J. Rare Dis.* 5, 29
124. Bruch, J. *et al.* (2015) Early neurodegeneration in the brain of a child without functional PKR-like endoplasmic reticulum kinase. *J. Neuropathol. Exp. Neurol.* 74, 850–857
125. Höglinger, G.U. *et al.* (2011) Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. *Nat. Genet.* 43, 699–705
126. Jousse, C. *et al.* (2003) Inhibition of a constitutive translation initiation factor 2alpha phosphatase, CREP, promotes survival of stressed cells. *J. Cell Biol.* 163, 767–775
127. Abdulkarim, B. *et al.* (2015) A missense mutation in PPP1R15B causes a syndrome including diabetes, short stature, and microcephaly. *Diabetes* 64, 3951–3962
128. Kernohan, K.D. *et al.* (2015) Homozygous mutation in the eukaryotic translation initiation factor 2alpha phosphatase gene, PPP1R15B, is associated with severe microcephaly, short stature and intellectual disability. *Hum. Mol. Genet.* 24, 6293–6300
129. Harding, H.P. *et al.* (2009) Ppp1r15 gene knockout reveals an essential role for translation initiation factor 2 alpha (eIF2alpha) dephosphorylation in mammalian development. *Proc. Natl. Acad. Sci. U. S. A.* 106, 1832–1837
130. Axten, J.M. *et al.* (2013) Discovery of GSK2656157: an optimized PERK inhibitor selected for preclinical development. *ACS Med. Chem. Lett.* 4, 964–968
131. Kanelakis, K.C. *et al.* (2009) Functional characterization of the canine heme-regulated eIF2alpha kinase: regulation of protein synthesis. *Adv. Hematol.* 2009, 251915
132. Raffie-Kolpin, M. *et al.* (2000) Two heme-binding domains of heme-regulated eukaryotic initiation factor-2alpha kinase. N terminus and kinase insertion. *J. Biol. Chem.* 275, 5171–5178
133. Rosen, M.D. *et al.* (2009) Discovery of the first known small-molecule inhibitors of heme-regulated eukaryotic initiation factor 2alpha (HRI) kinase. *Bioorg. Med. Chem. Lett.* 19, 6548–6551
134. Jammi, N.V. *et al.* (2003) Small molecule inhibitors of the RNA-dependent protein kinase. *Biochem. Biophys. Res. Commun.* 308, 50–57
135. Tsaytler, P. *et al.* (2011) Selective inhibition of a regulatory subunit of protein phosphatase 1 restores proteostasis. *Science* 332, 91–94
136. Baek, J.-H. *et al.* (2016) Unfolded protein response is activated in Lewy body dementias. *Neuropathol. Appl. Neurobiol.* 42, 352–365
137. Fogli, A. *et al.* (2002) Cree leukoencephalopathy and CACH/VWM disease are allelic at the EIF2B5 locus. *Ann. Neurol.* 52, 506–510
138. van der Knaap, M.S. *et al.* (2002) Mutations in each of the five subunits of translation initiation factor eIF2B can cause leukoencephalopathy with vanishing white matter. *Ann. Neurol.* 51, 264–270
139. van der Knaap, M.S. *et al.* (2003) eIF2B-related disorders: antenatal onset and involvement of multiple organs. *Am. J. Hum. Genet.* 73, 1199–1207
140. Brickwood, S. *et al.* (2003) Wolcott-Rallison syndrome: pathogenic insights into neonatal diabetes from new mutation and expression studies of EIF2AK3. *J. Med. Genet.* 40, 685–689
141. Durocher, F. *et al.* (2006) A novel mutation in the EIF2AK3 gene with variable expressivity in two patients with Wolcott-Rallison syndrome. *Clin. Genet.* 70, 34–38
142. Spehar Uroic, A. *et al.* (2014) Primary hypothyroidism and nipple hypoplasia in a girl with Wolcott-Rallison syndrome. *Eur. J. Pediatr.* 173, 529–531